NCT05276310 2026-04-21
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
Phase 1 Recruiting
ImmuneOncia Therapeutics Inc.
M.D. Anderson Cancer Center
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Anwita Biosciences
HC Biopharma Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Shanghai Allink Biotherapeutics Co., Ltd.